<DOC>
	<DOCNO>NCT02151903</DOCNO>
	<brief_summary>An open-label extension study enrol patient experience clinical benefit follow 6 cycle DI-Leu16-IL2 enrol Alopexx Oncology AO-101 study . Patients permit continue receive DI-Leu16-IL2 dose , schedule , route administration receive parent protocol . Prior pre-treatment ( e.g . Rituximab ) continue .</brief_summary>
	<brief_title>Open-Label Extension Study De-immunized DI-Leu16-IL2 Immunocytokine Administered Patients With B-cell NHL</brief_title>
	<detailed_description>1 . Primary Endpoints : • To continue provide DI-Leu16-IL2 patient currently enrol Alopexx Oncology trial AO-101 experience clinical benefit . 2 . Secondary Endpoints : - To continue evaluate safety DI-Leu16-IL2 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Patients currently enter Alopexx Oncology Protocol AO101 2 . Patient receive 6 cycle DILeu16IL2 Protocol AO101 3 . Documented clinical benefit follow 6th cycle DILeu16IL2 . 4 . Able begin extension study within 8 week receive 6th cycle DILeu16IL2 5 . Patients must receive prior Rituximabcontaining therapy . 6 . Patients participate study use adequate birth control measure ( abstinence , oral contraceptive , barrier method spermicide surgical sterilization ) study participation . Females childbearing potential must negative serum pregnancy test day dose . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month . 7 . Provide write informed consent prior study procedure . 1 . Pregnant lactate female . 2 . An immediate need palliative radiotherapy systemic corticosteroid therapy . 3 . Actively infected chronic carrier hepatitis B virus ( HBV ) demonstrate positive hepatitis B core antibody ( HbcAb ) hepatitis B surface antigen ( HbsAg ) . ( Patients seropositive , i.e. , surface antibody positive [ HbsAb ] , permit ) . 4 . Other significant active infection . 5 . Major surgery , chemotherapy , investigational agent , radiation within 30 day Day 1 . 6 . Uncontrolled hypertension ( diastolic ≥ 100 mmHg ) hypotension ( systolic ≤ 90 mmHg ) . 7 . History prior therapy serious , uncontrolled medical disorder Investigator 's opinion would impair participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NHL</keyword>
	<keyword>Immunocytokine</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin</keyword>
	<keyword>B-cell</keyword>
	<keyword>IL ( interleukin )</keyword>
</DOC>